CELZ · XBRL financial data
Creative Medical Technology Holdings financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CELZ's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 0 | 0 | 6 | 2 | 2 | 2 |
| Selling, general and administrative | 1 | 3 | 4 | 4 | 3 | 4 |
| Total operating expenses | 1 | 3 | 10 | 6 | 6 | 6 |
| Operating income (loss) | (1) | (3) | (10) | (6) | (6) | (6) |
| Interest expense | 1 | 4 | 0 | — | — | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (36) | 19 | (10) | (5) | (5) | (6) |
| Earnings per share, basic USD per share | (62.69) | 7.37 | (0.93) | — | — | — |
| Earnings per share, diluted USD per share | (62.69) | 5.61 | (0.93) | (3.76) | (3.71) | (2.52) |
| Weighted average shares, basic millions of shares | 1 | 3 | 11 | — | — | — |
| Weighted average shares, diluted millions of shares | — | 3 | 11 | 1 | 1 | 2 |
- † Share count changed about 1/174 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (CELZ's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 11 | 8 | 3 | 6 | 7 |
| Accounts receivable | 0 | 0 | 0 | — | — | — |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | — | 0 | 0 | 0 | 0 | 0 |
| Total current assets | 0 | 11 | 19 | 10 | 6 | 7 |
| Total assets | 1 | 11 | 19 | 11 | 7 | 8 |
| Accounts payable | 0 | 1 | 3 | 0 | 0 | 0 |
| Accrued liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | 41 | 1 | 3 | 0 | 0 | 0 |
| Total liabilities | 41 | 1 | 3 | 0 | 0 | 0 |
| Accumulated deficit | (62) | (44) | (54) | (59) | (65) | (71) |
| Total stockholders' equity | (40) | 10 | 16 | 10 | 6 | 8 |
| Total liabilities and equity | 1 | 11 | 19 | 11 | 7 | 8 |
| Common shares outstanding (cover page) millions of shares | 1,136 | 7 | 14 | 1 | 2 | 4 |
- † Share count changed about 1/174 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (CELZ's year ends in late December)
| In millions of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (36) | 19 | (10) | (5) | (5) | (6) |
| Stock-based compensation | 0 | 1 | 0 | 0 | 0 | 0 |
| Net cash from operating activities | (0) | (2) | (8) | (8) | (5) | (6) |
| Net cash from investing activities | (0) | 0 | (10) | 3 | 6 | (0) |
| Proceeds from issuing common stock | 0 | 15 | 15 | 0 | 2 | 7 |
| Share repurchases | — | — | 0 | 0 | 0 | 0 |
| Net cash from financing activities | 1 | 13 | 15 | (0) | 1 | 7 |
| Net change in cash | — | — | — | — | 2 | 1 |
- † Share count changed about 1/174 in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Creative Medical Technology Holdings | 8.7 | 0 | (1.5)* | 6.6M | 5.9 quarters | 10-QJun 30, 2026 |
| Target Group | 0 | 1.4 | (0.2)* | 617.0M | 0.1 quarters | 10-QJun 30, 2026 |
| Aspira Women's Health | 0.5 | 0 | (2)* | 46.6M | 0.2 quarters | 10-QJun 30, 2026 |
| Soligenix | 9.8 | not reported | (1.7)* | 21.8M | 5.7 quarters | 10-QJun 30, 2026 |
| Matinas BioPharma Holdings | 0.8 | not reported | (1.8)* | 14.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Synlogic | 13 | 0 | (0.9)* | 12.2M | 14.3 quarters | 10-QJun 30, 2026 |
| Viskase Holdings | 7.7 | 95 | 0.5* | 14.3M | — | 10-QSep 30, 2026 |
| China Pharma Holdings | 0.3 | 0.9 | (0)* | 43.0M | 9.3 quarters | 10-QJun 30, 2026 |
| Xenetic Biosciences | 6.5 | 0.7 | (0.9)* | 2.3M | 7.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.